Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 02/20/2026 | CALL | $51.00 | 28,218 | +27,741 | +5,815.72% |
| 02/13/2026 | PUT | $39.00 | 10,085 | +9,917 | +5,902.98% |
| 02/06/2026 | CALL | $46.00 | 5,689 | +5,673 | +35,456.25% |
| 12/18/2026 | CALL | $50.00 | 6,564 | +3,889 | +145.38% |
| 05/15/2026 | CALL | $60.00 | 3,486 | +2,920 | +515.90% |
| 01/21/2028 | CALL | $45.00 | 4,689 | +2,874 | +158.35% |
| 02/06/2026 | PUT | $60.00 | 35 | -1,331 | -97.44% |
| 02/06/2026 | PUT | $57.00 | 655 | -1,350 | -67.33% |
| 02/06/2026 | PUT | $55.00 | 208 | -2,071 | -90.87% |
| 02/06/2026 | PUT | $50.00 | 466 | -2,640 | -85.00% |
| 02/06/2026 | PUT | $52.00 | 145 | -2,931 | -95.29% |
| 02/06/2026 | PUT | $56.00 | 930 | -3,801 | -80.34% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Harbor Capital Appreciation Fund | 0.18% | 3.11M | 481.53M |
| Washington Mutual Investors Fund | 0.09% | 1.51M | 234.45M |
| Vanguard U.S. Growth Fund | 0.07% | 1.27M | 196.47M |
| Loomis Sayles Growth Fund | 0.07% | 1.18M | 183.13M |
| Fidelity Blue Chip Growth Fund | 0.07% | 1.13M | 175.35M |
| Amana Mutual Funds Trust-Growth Fund | 0.06% | 1M | 155.09M |
| PGIM Jennison Growth Fd | 0.05% | 828.11k | 128.15M |
| Blackrock Equity Dividend Fund | 0.04% | 712k | 110.18M |
| New Perspective Fund Inc | 0.04% | 691.44k | 107M |
| Price (T.Rowe) International Stock Fund | 0.04% | 674k | 104.3M |
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
02/07 10:30 pm
The Motley Fool
Read moreEli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore
02/06 03:15 pm
The Motley Fool
Read moreWhat's Going On With Novo Nordisk Stock On Friday?
02/06 02:51 pm
Benzinga
Read moreAnti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management
02/06 06:00 am
GlobeNewswire Inc.
Read moreHims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
02/05 09:51 pm
GlobeNewswire Inc.
Read moreAmazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
02/05 09:15 pm
The Motley Fool
Read morePharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026
02/05 08:53 pm
GlobeNewswire Inc.
Read moreOAK Family Advisors Sells $4 Million of NICE Stock
02/05 04:14 pm
The Motley Fool
Read moreHims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
02/05 01:51 pm
Benzinga
Read moreEli Lilly: Why Investors Are Rewarding It as Novo Slips
02/05 11:38 am
Investing.com
Read moreObesity Treatment Market Size to Reach USD 75.69 Billion by 2033 as the Treatment Offers a Comprehensive Evaluation of Therapeutic Developments Globally
02/05 05:00 am
GlobeNewswire Inc.
Read moreWhy Eli Lilly Stock Soared Today
02/04 11:18 pm
The Motley Fool
Read moreNovo Nordisk Faces a Reality Check as Pricing Pressure Hits 2026 Forecasts
02/04 03:22 pm
Investing.com
Read moreIn Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
02/04 03:02 pm
Benzinga
Read moreOzempic Maker Novo Nordisk Flags Declining Sales In 2026
02/04 07:52 am
Benzinga
Read moreNovo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales
02/03 02:56 pm
Benzinga
Read moreNovo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control
02/02 03:12 pm
Benzinga
Read moreNovo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
02/02 11:43 am
GlobeNewswire Inc.
Read more3 Headwinds Facing Pfizer in 2026
02/02 07:32 am
The Motley Fool
Read moreDemand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
01/30 07:24 pm
The Motley Fool
Read moreNovo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
01/30 01:57 pm
Benzinga
Read moreNovo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
01/30 11:08 am
Benzinga
Read more1 Biotech Stock Set to Rebound in 2026
01/28 02:30 am
The Motley Fool
Read more2 Pharmaceutical Stocks Set to Rebound in 2026
01/27 11:17 am
The Motley Fool
Read moreWhere Will Eli Lilly Be in 10 Years?
01/27 10:07 am
The Motley Fool
Read moreRoche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight
01/27 07:21 am
Benzinga
Read more3 Growth Stocks to Invest $1,000 in Right Now
01/24 09:15 pm
The Motley Fool
Read moreWeight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It
01/23 10:18 am
Benzinga
Read moreEli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
01/23 06:10 am
The Motley Fool
Read more2 Top Stocks to Double Up On Right Now
01/20 08:05 pm
The Motley Fool
Read moreWhat Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?
01/20 04:05 pm
The Motley Fool
Read moreEurope's Growth At Risk If Trump Acts On Greenland, Goldman Sachs Warns
01/19 02:05 pm
Benzinga
Read morePrediction: 2026 Will Be the Year of Eli Lilly
01/19 05:10 am
The Motley Fool
Read moreNovo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data
01/16 01:07 pm
Benzinga
Read moreWhy Eli Lilly Stock Gained 39.2% In 2025
01/14 02:13 pm
The Motley Fool
Read moreEli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
01/14 02:23 am
Investing.com
Read moreFDA Says No Clear Link Found Between Popular Weight Loss Drugs And Suicidal Thoughts, Review Ongoing
01/13 02:20 pm
Benzinga
Read moreEli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?
01/13 11:15 am
The Motley Fool
Read moreWegovy Pill vs Wegovy Shot: Oral vs Injectable Semaglutide Differences — 2026 FDA Launch Analysis via Ro.co
01/12 09:10 pm
GlobeNewswire Inc.
Read moreWegovy Pill Legitimacy Examined: 2026 Consumer Analysis Investigates Ro's Oral GLP-1 Access Pathway and No-Insurance Cash-Pay Options
01/12 07:45 pm
GlobeNewswire Inc.
Read moreStocks to Love in 2026
01/12 12:04 am
The Motley Fool
Read moreBest GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand
01/10 07:12 pm
GlobeNewswire Inc.
Read moreAscendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
01/09 07:01 pm
GlobeNewswire Inc.
Read moreAlveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme
01/09 04:13 am
GlobeNewswire Inc.
Read more